ANI Pharmaceuticals announced that its partner Dexcel has received approval from the Food and Drug Administration (FDA) for Donepezil HCl Tablets, the generic version of Eisai‘s Aricept

Donepezil HCl is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. 

RELATED: Alzheimer’s Drug Shortage Resolved

It is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase.

Donepezil HCl will be available as 23mg strength tablets. ANI and Dexcel plan to begin shipment of the product shortly. 

For more information call (800) 434-1121 or visit